Dublin, Dec. 10, 2018 (GLOBE NEWSWIRE) -- The "Lyme Disease (LD)- Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Lyme disease (LD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Lyme disease (LD) from 2016 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
According to this research, total incident population of Lyme disease (LD) in the 7 major markets is estimated approximately 489,605 cases in 2016 and it is expected to change in 2027.
This research estimates that the Incident population of Lyme disease (LD) will significantly change during the study period [2016-2027]. The research estimates a higher diagnosed incidence of Lyme disease (LD) in the United States with 280,152 diagnosed cases in 2016.
Currently, the therapeutic options comprises the use of antibiotics for the treatment of Lyme disease (LD). The present market does not holds any approved drug for Lyme disease (LD). The situation is equally crucial for the emerging therapies. The thin pipeline activities in this space makes the situation even more complicated. In the current scenario, the pipeline holds only one active product, VLA15 being developed by Valneva.
Expected Launch of potential therapies (currently only one i.e., VLA15) may increase market size in the coming years, assisted by an increase in diagnosed incident population of Lyme disease (LD). Owing to the positive outcomes during the early stage trials along with the Fast track Designation the only upcoming therapy VLA15 by Valneva has a potential to create a significant positive shift in the Lyme disease (LD) Market Size.
The treatment course for Lyme disease (LD) includes Antibiotics comprising Tetracycline (Doxycycline), Penicillins (Amoxicillin and Benzathine Penicillin), Cephalosporins (Cefuroxime, Ceftriaxone and Cefotaxime), Macrolides (Azithromycin and clarithromycin) and some other medications for the related manifestations associated with the Lyme disease (LD).
The First Line of Treatment for Lyme borreliosis comprises of Tetracycline, Penicillins followed by Cephalosporins.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to this research, the market of Lyme disease (LD) in 7MM was found to be 403.64 million in 2016, and is expected to increase from 2016-2027.
The United States accounts for the largest market size of Lyme disease (LD) in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Lyme disease (LD) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Key Topics Covered
1. Key Insights
2. Lyme disease (LD) Market Overview at a Glance
2.1. Market Share (%) Distribution of Lyme disease (LD) in 2017
2.2. Market Share (%) Distribution of Lyme disease (LD) in 2027
3. Disease Background and Overview: Lyme disease (LD)
3.4. Clinical Manifestations
3.4.1. Early Localized Disease
3.4.2. Early Disseminated Disease
3.4.3. Late Disease
3.5. Risk of Lyme disease (LD)
3.9. Differential Diagnosis
3.10.1. Early Localized Disease
3.10.2. Early disseminated Lyme disease (LD) (< 3 months)
3.11. Post-Treatment Lyme disease (LD) Syndrome (PTLDS)
4. Epidemiology and Patient Population
4.1. Key Findings
5.1.1. 7MM Total Incident Patient Population of Lyme disease (LD)
5.1.2. 7MM Total Diagnosed Patient Population of Lyme disease (LD)
6. Country Wise-Epidemiology of Lyme disease (LD)
6.1. United States
6.2. EU5 Countries
6.7. United Kingdom
7.1. Early localized disease (< 30 days)
7.2. Early disseminated Lyme disease (LD) (< 3 months)
7.3. Late Lyme disease (LD) (> 3 months)
8. United States Guideline on Lyme disease (LD)
9. European Guideline on Lyme disease (LD)
9.1. Adults and Young People (aged 12 and over)
9.2. In Children (Under 12)
10. Unmet Needs
11. Emerging Drugs
11.1. Key Cross Competition
11.2. VLA15: Valneva
12. Lyme disease (LD): 7 Major Market Analysis
12.1. Key Findings
12.2. Market Size of Lyme disease (LD) in 7MM
13. The United States Market Outlook
13.1. United States Market Size
13.2. Total Market size of Lyme disease (LD)
13.3. Market Size by Therapies
14. EU-5 Countries: Market Outlook
14.5. United Kingdom
15. Japan: Market Outlook
15.1. Japan market Size
15.2. Total Market size of Lyme disease (LD)
15.3. Market Size by Emerging Therapies
16. Market Drivers
17. Market Barriers
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/cj3v33/lyme_disease?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Infectious Diseases Drugs